

Book early and
save up to £540!

Exclusive discounts
for early stage biotechs

European Antibody Congress 2009

30 November – 2 December 2009, Crowne Plaza Hotel, Geneva, Switzerland

Day one: understanding structure-function relationships



Dr William Strohl
Senior Director, Antibody
Drug Discovery
Centocor (a Johnson & Johnson Company)



Dr Janine Schuurman
Associate Director, Research
GenMab



Dr Ralph Minter
Head of Research
Technology
MedImmune

Attack.



Discover. Develop. Get to market.

The World's largest event addressing global antibody trends, recent intra-market authorisation successes and critical clinical progress

Catumaxomab, certolizumab, rilonacept, ustekinumab and ofatumumab as well as the next generation of CD20 mAbs and IGF-1R mAbs will be exclusively presented

Major antibody structural improvements showcased

Including the latest global developments in 2-in-1 antibodies (Genentech), agonist antibodies (MedImmune, Kyowa-Kirin), Fc-engineered (Centocor, MedImmune) and non-activating formats (Genmab)

Unrivalled global participation from pharma and biotech with every key player in the antibodies market participating

International case studies from Abbott, Ablynx, Adnexus (BMS), Arius Research (Roche), Biogen Idec, Bayer Schering Pharma, Boehringer-Ingelheim, Centocor (JNJ), Fresenius Biotech, Genentech, GenMab, GSK (Domantis), Kyowa Kirin, MedImmune (AstraZeneca), Merck KGaA, Merck-Serono, Novartis, Pfizer Global R&D, Pierre Fabre, Regeneron, UCB-Celltech, Wyeth Research and many more...

1-2-1 partnering opportunities with 'Contact'

Schedule dedicated meetings within the industry's largest forum facilitating face-to-face networking with the leading industry players

Speaker line-up and content	page 2
Partnering opportunities	page 3
Conference programme	page 4-6
Sponsorship opportunities	page 7
All booking offers and options	page 8

Book early and SAVE up to £540

www.terrapiinn.com/2009/antibodyeu

Event sponsors and exhibitors:

Lonza



scil
proteins

BioWa



Produced by:
terrapiinn
use your brain

Day three: antibody innovation and alternatives



Dr Ray Camphausen
Associate Vice President,
Protein Design
Adnexus (a Bristol-Myers Squibb R&D Company)



Dr Ruud de Wildt
Manager, Biopharm
Research and Development
GlaxoSmithKline



Dr Hans-Peter Gerber
Senior Director, Tumor
Therapies
Wyeth Research

**Book early
and save up
to £540!**

**"Great coverage
of current field
of antibody
engineering and
development.
High quality
speakers!"**

Chengbin Wu,
Associate Research
Fellow,
**Abbott
Laboratories**

**"Great
overview of
current state
of the art of
the antibody
therapeutics
field, including
manufacturing"**

Conrad Savoy,
Chief Scientific
Officer,
Biopartners

**"Great
speakers, easy
interaction and
well organised
networking"**

Margarita Salcedo,
Head of Scientific
Strategy,
LFB

Industry's largest event for antibody discovery and development

Antibodies: a market and industry on the rise

The global monoclonal antibody market is writing new success stories every day, thanks to antibody development being witnessed ubiquitously. Beyond 2009, the industry will already be well on its way to **achieving compound annual growth of over 15%**, helping the biologics market move beyond a €80 billion valuation.

Monoclonal antibodies, as they continue to become critical resources in the therapeutic, diagnostic and drug discovery fields, continue to **deliver the kind of industry growth that other conventional pharmaceutical markets can only dream of**. With numerous blockbuster potential candidates having hit, and slated to hit, the market in the near term, **the growth is projected to rise even further**.

With the phenomenal growth in the market for monoclonal antibodies, it has become even more critical to **explore the diverse methods of design, engineering, production and application of technologies** to provide the antibodies needed for an ever widening group of targets.

That said, there still remains many critical R&D and strategic questions unanswered which must be tackled before big pharma, biotech and the wider service industry can **maximise and globally commercialise the full potential of monoclonal antibody research**.

3-Day Agenda at a Glance



Dr Alain Beck of Pierre Fabre will chair Day 1 on understanding structure-function relationships.

- Progress made in IgG2 and IgG4 formats by Dr William Strohl, **Centocor** and Dr Janine Schuurman, **GenMab**
- mAb effector functions and aggregation by Dr Shantha Raju, **Centocor** and Dr Satish Singh, **Pfizer Global R&D**
- Receptor agonisms and mAb agonistic activity by Dr Ralph Minter, **MedImmune** and Dr Shiro Kataoka, **Kyowa Kirin**
- Antigen/Gamma receptor co-crystallisation by Dr Carl Webster, **MedImmune** and Dr Jenny Bostrom, **Genentech**
- Antibody PK and metabolic studies by Dr Eric Ezan, **CEA** and Dr Olivier Heudi, **Novartis Institute for Biomedical Research**



Dr Robert Lutz of ImmunoGen will chair Day 2 on antibody advances and developmental success.

- Recent market authorisation case studies by Dr Diane Seimetz, **Fresenius Biotech**, Dr Sue Stephens, **UCB-Celltech**, Dr Neil Stahl, **Regeneron** and Dr Jacqueline Benson, **Centocor**
- Next generation CD-20 mAbs by Dr Paul Parren, **GenMab** and Dr Nadja Prang Richard, **LFB**
- Key IGF-1R mAbs clinical updates by Dr Stephen Demarest, **Biogen Idec** and Dr Dale Ludwig, **Imclone Systems**
- mAbs against new targets by Dr Nathalie Corvaia, **Pierre Fabre**, Dr Daniel Pereira, **Arius** and Dr Laetitia Devy, **Dyax**
- mAb production scale-up by Dr Rolf Werner, **Boehringer-Ingelheim**, Dr Wolfgang Noe, **Biogen Idec** and Dr Lothar Jacob, **Merck KgaA**



Dr Clive Wood of Bayer Schering Pharma will chair Day 3 on antibody innovation and antibody alternatives.

- Antibody humanisation by Dr Philippe Thullier, **Centre de Recherche du Service de Santé des Armées** and Dr Olivier Leger, **Merck Serono**
- Drug conjugate development by Dr Hans-Peter Gerber, **Wyeth Research**, Dr Iqbal Grewal, **Seattle Genetics** and Dr Jagath Junutula, **Genentech**
- Non-classical IgGs, bispecifics and intrabodies by Dr Mike Clark, **University of Cambridge**, Professor Stefan Dubel, **University of Braunschweig** and Dr Horst Lindhofer, **TRION Pharma**
- Domain antibodies and new scaffolds by Dr Ray Campchausen, **Adnexus**, Dr Ruud de Wildt, **GSK**, Dr Debbie Law, **Ablynx** and Dr Jijie Gu, **Abbott Laboratories**



a fully interactive experience

Industry's globally renowned congress

The 5th annual **European Antibody Congress** is the **Antibody industry's number one congress** for addressing the R&D, commercial application and manufacture of antibodies across the whole therapeutic landscape.

Featuring the World's most influential industry leaders from pharma, biotech and academia, **this exclusively diverse, globally recognised and internationally attended congress** combines **unique science with strategic deal making**.

The congress encompasses all that is hot right now.

Delivering pertinent, accurate and exclusive studies from an equally unmatched speaker faculty from pharma and biotech, you can be confident of hearing all that was successful in 2009 and debate all that has potential in 2010.

1-2-1 partnering**contact, connect, collaborate****contact** – your unique online partnering tool

Introducing you to your peers and your suppliers. 'Contact' is Terrapiinn's unique online introductory service. Don't leave meeting key attendees to chance. Identify your partners of choice, contact them before the congress, engage onsite and follow-up post event.

**– meet 120 attendees in just 60 mins**

Speed Networking is designed to quickly introduce you to half the congress attendees in one powerful 60 minute session, these meetings initiate contacts that often last well beyond the three days of the conference and blossom into fruitful and lasting business.

**– maximise your networking opportunities**

This year's European Antibody Congress we will be hosting two evening drinks receptions following the conference programme on the 30th November and 1st December. Take advantage of the informal setting to capitalise on those contacts made earlier in the day.

5 REASONS**Why you should attend:****1. Groundbreaking and innovative content that tackles the issues that matter**

Hear, learn, debate and act upon the year's most critical scientific and business opportunities and success stories

2. A speaker faculty comprising 90% pharma and biotech speakers

An agenda packed with over 50 of the World's leading experts in the antibody field

3. A proven track record – building on 4 years of success and 200+ annual attendees

European Antibody Congress has experienced growth in its attendance for each and every one of its previous 4 events

4. The one truly international industry congress for antibody professionals

Meet more diverse antibody industry profiles than ever before and from greater geographic regions

5. Unparalleled opportunities to build new business relationships

An attendee list that reads like the industry's who's who and over 12hrs of networking and 1-2-1 partnering opportunities

Key speakers include:

Dr Jijie Gu, Principal Scientist Biologics, **Abbott Laboratories**
- Dual specific antibody technology



Dr Debbie Law, Chief Scientific Officer, **Ablynx**
- Nanobody® technology development



Dr Daniel Pereira, Vice President of Research, **Arius Research (a Roche company)**
- Antibodies against novel targets



Dr Stephen Demarest, Senior Scientist Department of Protein Chemistry, **Biogen Idec**
- IGF-R inhibitory mAbs



Dr Rolf Werner, Corporate Senior Vice President of the Corporate Division Biopharmaceuticals, **Boehringer-Ingelheim**
- Maximising antibody yields



Dr Shantha Raju, Assistant Director, **Centocor (a Johnson & Johnson Company)**
- Glyco-engineered mAbs



Dr Paul Parren, Senior Vice President, **Research and Development, GenMab**
- CD20 therapeutic antibodies



Dr Olivier Heudi, Laboratory Head, Translational Sciences DMPK/Bioanalytics, **Novartis Institutes for Biomedical Research**
- Quantification of mAbs in serum



Dr Alain Beck, Head of Physio-Chemistry Department Centre d'Immunologie, **Pierre Fabre**
- mAbs homogeneity and drugability



Dr Neil Stahl, Senior Vice President, Research and Development Sciences, **Regeneron**
- First in class Fc fusion proteins

"An awful lot of networking opportunities and very well organised"

Leeanne Lewis,
Research Scientist,
MedImmune

"Excellent conference with lots of great speakers and presentations plus excellent networking opportunities"

Radmila Micanovic,
Research Advisor,
Eli Lilly and Company Limited

"Excellent organisation, and plentiful opportunities for networking and interaction with prospects. Great speakers and high information quality"

Juan Carlos Almagro,
Research Fellow,
Centocor (a Johnson & Johnson company)

Congress Day 1 Monday 30 November 2009


- 09.00 Chairman's opening remarks**
Dr Alain Beck, Head of Physio-Chemistry Department, **Centre d'Immunologie Pierre Fabre**

CHOOSING THE RIGHT FORMAT FOR THE RIGHT INDICATION

- 09.05 Modifications to IgG2m4 resulting in antibodies devoid of effector functionality for therapeutic development**
- Antibodies devoid of effector function are needed when targeting receptors on immune cells
 - IgG2 presents a good, and now proven, scaffold from which to make Fc-silenced antibodies
 - Ecolizumab Fc, IgG2m4, and other similar approaches will be compared
- Dr William Strohl**, Senior Director, Antibody Drug Discovery, **Centocor (a Johnson & Johnson Company)**

- 09.30 Progressing IgG4, Unibody and other nonactivating antibody formats**
- Considerations for the clinical development of non-activating formats
 - Therapeutic IgG4 antibodies engaging in Fab-arm exchange with patient's IgG4 in vivo
 - Developing UniBody as a nonactivating format
- Dr Janine Schuurman**, Associate Director, Research, **GenMab**

IMPROVING EFFICACY AND DRUGABILITY OF mAbs

- 09.55 Improving mAbs homogeneity and drugability: lessons learned from structure-function relationship studies**
- IgGs structure and micro-variants assessment by Mass Spectrometry
 - IgG lead design and optimisation to improve potency, stability, homogeneity and batch comparability
- Dr Alain Beck**, Head of Physio-Chemistry Department, **Centre d'Immunologie Pierre Fabre**
- 10.20**  **11.20 Morning coffee**
- 11.50 Influence of terminal sugars of Fc glycans on mAbs effector function of IgGs**
- Glyco-engineered mAbs with improved cytotoxicity for malignancies
 - Glyco-engineered mAbs with improved anti-inflammatory properties for autoimmune and inflammatory diseases
- Dr Shantha Raju**, Assistant Director, **Centocor (a Johnson & Johnson Company)**

- 12.15 Insights into Receptor Agonism – an exploration of antibodies to the Fas Receptor**
- Fas receptor is a tumour-associated antigen which, when ligated by Fas ligand, triggers cell apoptosis
 - Using phage display we have isolated an agonistic antibody to Fas receptor which can initiate apoptosis in cancer cells
 - Through protein engineering and structural studies we are exploring the agonistic mechanism, which could have implications for agonistic antibodies to other therapeutic targets
- Dr Ralph Minter**, Head of Research Technology, **MedImmune**

- 12.40 Antibody agonist vs Ligand: switching constant domains to enhance mAb agonistic activity**
- KM mouse technology can efficiently generate agonistic antibodies
 - The agonistic activity can be modified by domain switching technology
 - Agonistic antibody technology provides safer long acting agents for chronic patients
- Dr Shiro Kataoka**, Senior Manager, Licensing Group, **Kyowa Hakko Kirin Co.**

- 13.05 Networking lunch**

- 14.05 Potelligent® CHOK1SV: evolution of the GS Gene Expression System™**
- Antibody-dependent cellular cytotoxicity activity as a critical effector function for many therapeutic antibodies
 - Generating recombinant cell lines suitable for cGMP manufacture and expressing 100% non-fucosylated antibodies
- Dr Alison Porter**, Senior Science Leader, Cell Culture Process Development, **Lonza**

- 14.30 Reducing the aggregation issues of mAbs**
- Identification of motives prone to aggregations
 - Immunogenicity linked to aggregations
 - Improving solubility of mAbs at high concentration
- Dr Satish Singh**, Research Fellow, Global Biologics R&D, **Pfizer Global R&D**


Fab/ANTIGEN OR Fc/Fc-GAMMA RECEPTORS CO-CRYSTALLISATION STUDIES

- 14.55 Structural characterisation of a human Fc fragment engineered for extended serum half-life**
- First 3D-dimensional structure of a human Fc fragment genetically engineered for improved pharmacokinetics properties
- Dr Carl Webster**, Head of Research Technology, **MedImmune**
- 15.20 Designing the next generation of mAbs based on Fab / antigen co-crystallisation studies**
- Structural basis of CD20 recognition by rituximab and ocalizumab and fine epitope mapping of omalizumab
 - Structural basis of LF3-1 recognition by efalizumab
- Dr Yajun Guo**, Director and Professor, **Chinese National Engineering Center for Antibody Medicine**

- 15.45 Afternoon tea**

- 16.15 Two-in-One antibodies: Herceptin Variants that bind both VEGF and HER2 with high affinity**
- The ability of an antigen-binding site to interact with two unrelated proteins was explored by protein engineering
 - bH1 binds VEGF and HER2 with high affinity and inhibits both HER2 and VEGF-mediated cell proliferation
- Dr Jenny Bostrom**, Post Doctoral Fellow and Scientist, **Genentech**

ANTIBODY PK AND METABOLIC STUDIES

- 16.40 Quantitative analysis of mAbs in biofluids by mass spectrometry**
- Analysis of therapeutic antibodies in biological fluids necessary for preclinical studies of pharmacokinetics and toxicity
 - Recent advances and the advantages of mass spectrometry for the quantification of therapeutic antibodies in biofluids
- Dr Eric Ezan**, Head, Pharmacology and Immunanalytics, **CEA**
- 17.05 Towards absolute quantification of therapeutic monoclonal antibody in serum**
- LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry
 - Novel LC-MS/MS method as a simple, rapid, and precise approach for the therapeutic mAb quantification to support preclinical and clinical studies
- Dr Olivier Heudi**, Laboratory Head, Translational Sciences **DMPK/Bioanalytics, Novartis Institute for Biomedical Research**
- 17.30 Close of Day 1 followed by networking drinks** 

Congress Day 2 Tuesday 1 December 2009

- 09.00 **Chairman's opening remarks**
Dr Robert Lutz, Executive Director, **ImmunoGen**

ANTIBODY SUCCESSES AND ATTRITION RATES

- 09.05 **Human antibody and Ab fragment development trends**
- Human mAb marketing approval success rates
 - Progress in the antibody fragment clinical pipeline
- Dr Janice Reichert**, Senior Research Fellow, **Tufts Center for the Study of Drug Development** and Editor-in-Chief, **mAbs**

TRIFUNCTIONAL ANTIBODY, Fab FRAGMENT AND Fc-FUSION PROTEIN SUCCESSES

- 09.25 **Case study: a positive opinion EMEA for catumaxomab trispecific antibody**
- Trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3)
 - Clinical development and approval process in the EU
- Dr Diane Seimetz**, Chief Scientific Officer and Executive Vice President, **Fresenius Biotech**

- 09.50 **Case study: certolizumab - are all anti-TNFs the same?**
- Structure for anti-TNF that is univalent and PEGylated
 - Effect on affinity: conferring beneficial effects on the molecule
- Dr Sue Stephens**, Senior Director, Nonclinical Development, **UCB-Celltech**

- 10.15 **Case study: rilonacept - Fc fusion protein first in class to antagonise IL1R**
- Rilonacept (IL-1 Trap) as an Interleukin-1 (IL-1) blocker
 - Fusion protein designed to attach and neutralise circulating IL-1
- Dr Neil Stahl**, Senior Vice President, Research and Development Sciences, **Regeneron**

- 10.40 **Case study: ustekinumab (anti-IL-12/23p40) discovery and mechanism of action**
- Neutralisation of IL-12 and IL-23 bioactivity
 - IL-12/23p40 and preventing interaction with IL-12Rb1
- Dr Jacqueline Benson**, Assistant Director, Immunology Research, **Centocor (a Johnson & Johnson Company)**

- 11.05 **Morning coffee**

ADVANCING CD20 mAbs IN CLINICAL DEVELOPMENT

- 11.35 **Arzerra (ofatumumab): a novel CD20 therapeutic antibody**
- Arzerra mechanism of action and clinical experience
 - Role of antibody effector function in cell killing
- Dr Paul Parren**, Senior Vice President, Research and Development, **GenMab**

- 12.00 **Recombinant mAbs with enhanced ADCC in clinical trials: anti-CD20 and anti-Rhesus D**
- EMABling technology applied to mAbs in early clinical trials
- Dr Nadja Prang-Richard**, Program Director, Monoclonal Antibody Development, **LFB**

IGF-1R mAbs IN CLINICAL DEVELOPMENT

- 12.25 **IGF-R inhibitory mAbs: competitive or allosteric ligand blockade?**
- Update on BIIB022 mAb clinical trial
 - Aglycosylated (T299A) IgG4 format for an anti-cancer mAb
- Dr Stephen Demarest**, Senior Scientist, Department of Protein Chemistry, **Biogen Idec**
- 12.50 **Therapeutic antibodies to the Type 1 IGF Receptor (IGF-IR)**
- Targeting insulin-like growth factor type-I receptors
 - Preclinical experience and clinical opportunity
- Dr Dale Ludwig**, Vice President, Department of Molecular & Cellular Engineering, **ImClone Systems**

- 13.15 **The SH3-domain of Fyn Kinase as a scaffold for the generation of novel binding proteins**
- Engineering Fynomers for binding high affinity and specificity
 - Fynomer formats improving versatility therapeutic platforms
- Dr Simon Brack**, Head of Lead Discovery, **Covagen**

- 13.35 **Networking lunch**

mAbs AGAINST NEW TARGETS AND PRECLINICAL STUDIES

- 14.35 **Safety assessment and dose selection for First-in-Man clinical trials with immunomodulatory mAbs**
- Risk mitigation for adverse immune-mediated drug reactions
 - Safety relevant differences between non-human primate and human immune systems, species selection/qualification
- Dr Patrick Mueller**, Project Leader, Safety Assessment, **Novartis Institutes for BioMedical Research**

- 15.00 **Discovery and development of new anti-cancer antibodies**
- Functional approaches and proteomics
 - Targets for oncology and anti-proliferative antibodies
- Dr Nathalie Corvaia**, Head of Research, **Centre d'Immunologie Pierre Fabre**

- 15.25 **Discovery and development of antibodies against new targets**
- Antibody epitope efficacy and cell signal/death as a measurable
 - Antibody candidates developed through functional screens
- Dr Daniel Pereira**, Vice President of Research, **Arius Research (a Roche company)**

- 15.50 **Choosing highly selective matrix metalloprotease inhibitors for oncology and inflammation**
- Discovery of selective MMP inhibitor antibodies
 - A highly selective fully human MMP-14 inhibitory antibody
- Dr Laetitia Devy**, Associate Director, Cell Biology, **Dyax Corp.**

- 16.15 **Revolutionary antibody therapy against seasonal and pandemic flu**
- Antibody recognition of a highly conserved influenza virus epitope
- Dr Jaap Goudsmit**, Chief Scientific Officer, **Crucell**

- 16.35 **Afternoon tea**

ANTIBODY PATENTS

- 17.00 **Antibody patent level protection and implications for development**
- Trends in successful patent applications
 - How to obtain meaningful patent protection
- Dr Tony Maschio**, Partner, Life Sciences and European Patent Attorney, **Edwards, Angell, Palmer & Dodge LLP**

mAb PRODUCTION AND SCALE-UP

- 17.25 **Biopharmaceutical manufacturing trends for maximising antibody yields**
- Market direction and manufacturing technology requirements
 - Which product tool box technologies can be put in place?
- Dr Rolf Werner**, Corporate Senior Vice President, Corporate Division Biopharmaceuticals, **Boehringer - Ingelheim**

- 17.50 **Exploiting a paradigm shift in antibody based manufacture**
- Progress to date in cell culture, purification and formulation
 - Analysis of technology gaps in the antibody industry
- Dr Wolfgang Noe**, Vice President, Strategic Development and Technical Alliance, **Biogen Idec**

- 18.15 **Protein purification and improved production strategies**
- Antibody purification methods and manufacturing capacity
 - Strategic planning to ensure quick and efficient purification
- Dr Lothar Jacob**, Technical Marketing Manager, **Merck KGaA**

- 18.40 **Close of Day 2 followed by networking drinks**



Congress Day 3 Wednesday 2 December 2009

- 09.00 Chairman's opening remarks**
Dr Clive Wood, Chief Scientific Officer, **Bayer Schering Pharma**

ANTIBODY HUMANISATION, 'SUPERHUMANISATION' AND ENGINEERING

- 09.05 Antibody humanisation and engineering: what do we learn from IMGT® standardisation?**
 • IMGT Colliers de Perles and CDR-IMGT delimitations
Professor Marie-Paule LeFranc, Senior Member, IUF, Chair of Immunogenetics and Immunoinformatics, IMGT Founder and Director, **Université Montpellier**
- 09.30 Combining non-human primate immune libraries with germline humanisation**
 • Isolation of high affinity antibody fragments and 'Germline super-humanisation'.
Dr Philippe Thullier, Head, Antibody-Related Technology Group, **Centre de Recherche du Service de Santé des Armées**
- 09.55 Critical mAb humanisation trends**
 • Current developments with humanised antibody constructs
Dr Olivier Leger, Senior Scientist, Protein Engineering and Antibody Group, **Merck-Serono**
- 10.20 Antibody cloning: a novel approach to recovering the complete immune repertoire**
 • Non biased amplification of immunoglobulin variable domains and full-length expressed antibody sequences
Dr Peter Lowe, Senior Scientist, Protein Engineering, **Centre d'Immunologie Pierre Fabre**
- 10.45 Morning coffee**

ANTIBODY-DRUG CONJUGATE DEVELOPMENT

- 11.10 Pre-clinical and clinical development of Calicheamicin derivatives conjugated to mAbs**
 • Preclinical and clinical updates on Gemtuzumab Ozogamicin and CMC-544
Dr Hans-Peter Gerber, Senior Director, Tumor Therapies, **Wyeth Research**
- 11.35 Potent antibody-drug conjugates for Cancer immunotherapy**
 • Auristatin-based antibody-drug conjugates provide enhanced antitumor activity of the antibody and reduced toxicity
Dr Iqbal Grewal, Vice President, Preclinical Therapeutics, **Seattle Genetics**
- 12.00 Antibody-Maytansinoid conjugates for the treatment of cancer - bench to clinical success**
 • Recently unveiled linkers providing new opportunities for next generation conjugates
Dr Robert Lutz, Executive Director, **ImmunoGen**
- 12.25 THIOMAB platform: antibody-drug conjugates with the improved therapeutic index**
 • Developed THIOMAB technology platform for site-specific attachment of cytotoxic drugs
Dr Jagath Junutula, Scientist/Group Leader, **Genentech**
- 12.50 Networking lunch**

NON CLASSICAL IgGS: AGLYCOSYLATED, BISPECIFICS AND INTRABODIES

- 13.40 Aglycosylation and other Fc modifications for improved clinical efficacy**
 • Otelixizumab case study (ToleRx, Inc, anti-CD3, Phase III, immunosuppression of graft rejection)
Dr Mike Clark, Reader in Therapeutic and Molecular Immunology, **University of Cambridge, UK**

- 14.05 'Genome Scale' selections - pilot projects and antibody genes for functional genomics**
 • A streamlined pipeline for antibody generation
 • The SH2 Pilot Project of the Structural Genomics Consortium
 • Using genes of selected antibodies for functional genomics
Professor Stefan Dübel, Director, Department of Biotechnology, **University of Braunschweig, Germany**

- 14.30 Trifunctional antibodies: what's so different?**
 • Passive, active immunisation and immunogenicity
 • Targeting of cancer stem cells
Dr Horst Lindhofer, Chief Executive Officer, **TRION Pharma**

BEYOND ANTIBODIES: DOMAIN ANTIBODIES AND NEW SCAFFOLDS

- 14.55 Multi-specific Adnectins: realising the promise of a novel class of targeted biologics**
 • Generating bispecific targeted biologics using modular binding units called Adnectins™
Dr Ray Camphausen, Associate Vice President, Protein Design, **Adnexus (a Bristol-Myers Squibb R&D Company)**
- 15.20 Applying Affilin™ technology to discover, develop and commercialise a new generation of products based on human-derived binding proteins**
 • Ubiquitin-based binding Affilin® molecules offering the advantage of using standard animal models even for chronic treatments and predicting the immunogenicity of candidates
Dr Arnd Steuernagel, Chief Scientific Officer, **Scil Proteins**
- 15.40 Afternoon tea**
- 15.55 Pulmonary dAb platform development and ongoing pipeline and technology**
 • Clinical utility of domain antibodies for treatment of pulmonary disease
Dr Ruud de Wildt, Manager, Biopharm Research and Development, **GlaxoSmithKline**
- 16.20 Nanobody® development: a novel class of antibody-derived therapeutic proteins**
 • Broad applicability of the Nanobody® technology to different target classes and therapeutic areas
Dr Debbie Law, Chief Scientific Officer, **Ablynx**
- 16.45 Development of dual-specific antibody technology and DVD formats**
 • Platform technology with strategic benefits for biopharmaceutical R&D
Dr Jijie Gu, Principal Scientist, Biologics, **Abbott Laboratories**
- 17.10 Discovery and development of human protease inhibitors from an engineered scaffold library**
 • Discovery and development of ecallantide, a potent and specific plasma kallikrein inhibitor
Dr Andrew Nixon, Vice President, Lead Discovery and Biochemistry, **Dyax Corp.**
- 17.35 DARPin as a promising class of non-immunoglobulin proteins for target binding**
 • DARPins used for the inhibition of kinases, proteases and drug-exporting membrane proteins
Dr Kaspar Binz, Vice President, Technology, **Molecular Partners**
- 18.00 Close of congress**

Become a sponsor at the industry's largest antibody congress

Monoclonal antibodies are currently the fastest growing sector of the biopharmaceutical industry. They possess colossal potential to revolutionise the treatment of a variety of unmet diseases and disorders. **Companies already supplying this market are clamouring to be the supplier of choice** as pharma and biotech take developments to the next level. Those new to this industry need to find their commercial angle in gaining a strategic foothold.

Create and nurture new business relationships

Building on the success of the previous four years, the *European Antibody Congress* will continue to serve as Europe's most influential meeting place for the antibody community in 2009 and beyond. **The congress continues to support the antibody industry by connecting biotechs, pharmaceutical companies and antibody manufacturers** with the suppliers they need to get the job done.


The *European Antibody Congress* offers a succinct promotional and commercial development solution to companies that wish to position themselves at the forefront of the antibody sector. **This is a major opportunity to enhance branding, reputation and sales by engaging face-to-face with your target audience.**

A complete marketing and sales solution

This is your chance to be seen as a market leader and present your message to executives driving the global antibody market.

If your company falls into one of the categories below then the *European Antibody Congress* offers you a unique platform to stand out from the crowd.

Contact us TODAY for a tailored sponsorship package to meet your business objectives. Contact Caoilfhionn Lee on +44 (0)207 827 5970 or email c.lee@terrapiinn.com



Our sponsors and exhibitors



Our media partners



Who attends:

Abbott Bioresearch
Abbott Laboratories
Abylnx
Adnexus
AFSSAPS
Algonomics
Amgen
Antitope
Arius Research
Athera Biotechnologies
Baxter Innovation
Bayer Healthcare
Biogen Idec
Biogenes
Boehringer Ingelheim
Centocor
Centre d'Immunologie
Pierre Fabre
Chugai Pharmaceutical
Covagen
Crucell
CSL Limited
Direvo Biotech
Domantis
Dyax Corporation
Eli Lilly and Company
European Commission
F. Hoffman La Roche
Fresenius Biotech
Genentech
Geneuro
GenMab
Genovis
Genzyme
GlaxoSmithKline
GlycArt Biotechnology
ImClone Systems
ImmunoGen
Kyowa Hakko Kirin Co.
Medarex
MedImmune
Merck & Co.
Merck KGaA
Merck Research Laboratories
Merck-Serono
Molecular Partners
MorphoSys
National Institutes of Health (NIH)
NeurImmune
Novartis Institutes for BioMedical Research
Novartis Pharma
NovImmune
Novo Nordisk
Organon
Pangenetics
Paul-Ehrlich-Institut
Pfizer Global R&D
Regeneron
sanofi pasteur
sanofi-aventis
Sanquin Research
Seattle Genetics
TRION Pharma
UCB-Celltech
Wyeth Pharmaceuticals
Wyeth Research

European Antibody

 Congress 2009

Attack.



30 November – 2 December 2009, Crowne Plaza Hotel, Geneva, Switzerland

Use our online calculator at
www.terrapiinn.com/2009/antibodyyeu

**You can use our online calculator to tailor your ticket and buy multiple tickets.
The calculator automatically selects the most favourable discount for you.**

Register now

Package	Before 11 Sep 09	Before 23 Oct 09	Before 14 Nov 09	After 15 Nov 09	How many	Calculate your ticket
3 day congress	£2,425 SAVE £540!	£2,695 SAVE £270!	£2,830 SAVE £135!	£2,965	<input type="checkbox"/>	
<p>* Registrations without credit/debit card payments are subject to a £100 booking fee.</p> <p>All tickets include refreshments, lunch and full conference documentation. The fee does not include hotel accommodation.</p>			How do you want to pay?			
			Credit / Debit card	<input type="checkbox"/>	£ 0	
			Cheque / Bank transfer	<input type="checkbox"/>	£ 100	
			Total			

Biotech Discounts

☐ Yes. I am a small / early stage biotech. I therefore qualify for an exclusive discount.
Call Neil Darkes now to find out more details +44 (0)20 7092 1240.

Your details

Delegate name.....

Job title..... Organisation.....

Address

Post code..... Country.....

Tel..... Fax.....

Email.....

Authorising manager..... Authorising manager signature

Bring your team and save more.

	Mr/Mrs/Ms	Full name	Job title	Telephone
1				
2				

For groups of more than 2 please attach a separate sheet with details of all attendees. Alternatively call +44 (0) 207 242 2324.

Payment details

Payment terms are 14 days from date of invoice. Notwithstanding this, payment must be received prior to the conference taking place. Kindly note the terms and conditions on our registration page.

☐ Bank transfer ☐ Invoice me ☐ Credit card ☐ Diners club ☐ Visa ☐ American express ☐ Mastercard

Card number - - Expiry date: / /

Card holders name Card holders signature

Bank Transfers: Account Name: Terrapinn Limited, Sort Code: 20-78-98, Bank account number: 30412791, Bank Name & Address: Barclays Bank PLC, 27 Soho Square, London, W1D 3QR, Swift Address: BARCGB22, IBAN: GB14 BARC 2078 9830 4127 91. **Reference: please quote 141592 and the delegate's name**

How to book your ticket

Online

www.terrappinn.com/2009/antibodyeu
You can use our online calculator to tailor your ticket and buy multiple tickets. The calculator automatically selects the most favorable discount for you. If you book and pay online you also save a further £100.

Offline

You can use our online calculator to tailor your ticket and then print a pdf of your order and fax to +44 (0)20 7242 2320 or complete this form and fax to +44 (0)20 7242 2320 or call +44 (0)20 7242 2324 and we'll take your booking over the phone.

Group bookings

Why not send your team and save more.

Send 3 delegates and save 10%

Send 6 delegates and save 20%

Send 8 delegates and save 25%

To register a group either call +44 (0)20 7092 1250 or fax this form to +44 (0) 207 242 2320.

Privacy policy

Terrapinn may contact you about products and services offered by Terrapinn and its group companies, which Terrapinn believes may be of interest to you, or about relevant products and services offered by reputable third parties. Please tick the appropriate box if you do not wish to receive such information from:

☐ the Terrapinn group; ☐ or reputable third parties.

Cancellation policy

1. Should you be unable to attend, a substitute delegate is welcome at no extra charge.
2. Terrapinn does not provide refunds for cancellations. Invoiced sums are payable in full, except in cases where Terrapinn has been able to mitigate loss.
3. Terrapinn will make available course documentation to a delegate who is unable to attend and who has paid.
4. Terrapinn reserves the right to alter the programme without notice including the substitution, alteration or cancellation of speakers and / or topics and / or the alteration of the dates of the event.
5. Terrapinn is not responsible for any loss or damage as a result of a substitution, alteration, postponement or cancellation of an event.

Don't forget huge discounts are available for group bookings. See above for details.



We lessen this brochure's impact on the environment by using recycled paper.